Abstract:
A three-phase 48-pulse rectifier transformer includes two 24-pulse rectifier transformers phase-shifted through valve-side output windings. Each 24-pulse rectifier transformer has two sets of grid-side input windings and four sets of valve-side output windings. The two sets of grid-side input windings are connected in parallel and axially arranged in a split manner. Among the four sets of valve-side output windings, two sets of valve-side output windings are radially arranged in a split manner corresponding to one set of grid-side input windings, and the other two sets of valve-side output windings are also radially arranged in a split manner corresponding to the other set of grid-side input windings. The two sets of valve-side output windings that are radially split and the other two sets of valve-side output windings that are radially split are axially arranged in a split manner. The grid-side input windings of the two 24-pulse rectifier transformers are phase-shifted with respect to each other. In this way, a uniform difference of 7.5° is produced in voltages of the eight sets of valve-side output windings of the two 24-pulse rectifier transformers, and the eight sets of valve-side output windings of the two 24-pulse rectifier transformers are correspondingly connected to rectifiers to form a uniform 48-pulse rectifier transformer, which not only reduces the harmonic current generated by the rectifier, but also improves the load capacity of the rectifier.
Abstract:
The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.
Abstract:
The present invention discloses a cell bottom structure of a reduction cell which comprises a reduction cell and a cathode bus, wherein the bottom of the reduction cell is provided with column-shaped cathode carbon blocks perpendicular to the bottom of the reduction cell, and a lower end of the column-shaped cathode carbon block is connected to the cathode bus. By means of inserting the column-shaped cathode carbon blocks perpendicular to the bottom of the reduction cell and connecting the lower end of the column-shaped cathode carbon block with the cathode bus, such that electrical current that guided from anode carbon blocks is guided through the molten aluminum to the column-shaped cathode carbon blocks and is downwardly guided out, the present invention reduces horizontal electrical current in the molten aluminum, such that the cathode extending into the molten aluminum can effectively reduce fluctuations of the molten aluminum to obtain a stable surface of the molten aluminum, thereby reducing a polar distance between a cathode and an anode and lowering cell voltage so as to achieve the object of lowering electricity consumption.
Abstract:
In a Wavelength Division Multiplexed Passive Optical Network (WDM-PON) including, a system for overlaying an analog broadcast signal. An Optical Line Terminal of the WDM-PON includes a broadband light source for generating uplink seed light for each uplink channel of the WDM-PON, and a modulator for modulating the analog broadcast signal onto the uplink seed light. An Optical Network Terminal of the WDM-PON receives the uplink seed light from the Optical Line Terminal, and includes an optical divider for dividing the received seed light into a first signal and a second signal; a light source for generating an uplink data signals using the first signal as seed light; and an RF receiver for detecting the analog broadcast signal modulated on the second signal.
Abstract:
One or more embodiments of the present invention provide a novel composition for gene delivery are directed to a group of polysaccharide polymers, having one or more nucleic acid delivery side chains comprising cationic peptides. In some embodiments, these cationic peptides condense and physically bond to one or more nucleic acids to form a polysaccharide-nucleic acid complex that permits delivery to and transfection of the nucleic acid(s) into cells. In some embodiments, the polysaccharide polymers of the present invention may also have one or more zwitterionic side chains and/or reactive side chains.
Abstract:
A cathode boss structure for an aluminum electrolytic cell is disclosed. The cathode boss is arranged on the top surface of the cathode carbon block or on the top of the gap between two cathode carbon blocks. The distance between cathode bosses is 400 mm-900 mm. The length of the throughout elongate cathode boss is 100-250 mm longer than that of cathode carbon block, and two ends thereof are directly embedded into the paste around lateral portion. The length of the embedded and butted cathode boss is in a range of 3000-3200 mm, two ends thereof are fixed by binding carbon blocks respectively, and the binding carbon blocks are embedded into the paste around lateral portion. The cross-section of the cathode boss structure is in the shape of rectangle or isosceles trapezoid. The cathode boss structure is applicable to all types of current electrolytic cells. The strip boss is implanted into the top surface of the cathode of the electrolytic cell conveniently and quickly when the lateral portion of the common electrolytic cell is rammed, thereby forming a “choking effect”, reducing the flow rate of the aluminum liquid layer, decreasing energy dissipation from the aluminum liquid layer, therefore improving the production stability of the electrolytic cell and reducing energy consumption.
Abstract:
A device using the live welding method for aluminum electrolytic cell overhauling under series full current consists of short-circuit buses at the bottom of the cell (1), pillar buses (2), an anode bus (3), a balance bus (4), a inter-cell standby bus (5), a door-shaped pillar clamp (6), an arcuate clamp (7) of anode buses, a current conversion switch (8, a mechanical switching device (9) for the short-circuit port, a voltage sensor and wires thereof (10), a temperature sensor and wires thereof (11), a system (12) for data acquiring, displaying, analyzing and alarming, an A-side welding area (13), a B-side welding area (14) and compression-joint points (15) on pillar soft belts of overhauling cells; and the live welding method comprises the following steps: when welding is required to be performed in some zone, the currents of short-circuit buses at the bottom of the cell (1) and pillar buses (2) which influence the welding area most are cut off, the serial currents are shunted to other pillar buses (2), other buses at the bottom of the cell (1) and the inter-cell standby buses (5) such that the magnetic field intensity at the welding area can be lowered to the extent that welding can be performed so as to perform welding, and such a device and method can achieve live welding of aluminum electrolytic cells overhauling under series full current.
Abstract:
The present invention is directed to a compound of Formula (I) wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).
Abstract:
A high temperature protective valve and the use thereof in a shower head, wherein the high temperature protective valve includes a body, the body having a complete one-way waterway, and also a thermo-sensitive assembly and a pivot valve assembly. The thermo-sensitive assembly is fixed inside the body and has a memory alloy body which can be immersed in the waterway and extend and retract along the direction of the flow. The pivot valve assembly is also fixed inside the body downstream waterway of the thermo-sensitive assembly. The pivot valve assembly has a pivot valve plug which is controllable by the thermo-sensitive assembly so as to cut off the waterway. The high temperature protective valve of such a structure has a fast response and can achieve good protective effects at a high temperature.